Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Biomarker Discordance During Tumor Progression
Guest editors: Naoki Niikurax and Naoto T. Uenoy
Article type: Research Article
Authors: Dawood, Shaheenahb; * | Gonzalez-Angulo, Ana M.a
Affiliations: [a] Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | [b] Department of Medical Oncology, Dubai Hospital, Dubai, UAE | [x] Department of Breast and Endocrine Surgery, Tokai University School of Medicine, Kanagawa, Japan | [y] Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence: [*] Corresponding author: Shaheenah Dawood, MRCP (U.K), Department of Medical Oncology, Dubai Hospital, Department of Health and Medical Services P.O.Box 8179, Dubai, UAE. E-mail: Shaheenah_d@yahoo.com.
Abstract: With the increasing use of neoadjuvant chemotherapy it is increasingly being observed that differences in the status of molecular markers may exist between core biopsy specimens and the residual disease in the breast post chemotherapy. Several hypotheses have been postulated to explain the biomarker discordance observed following neoadjuvant chemotherapy including intratumor heterogeneity, technical variance in the assays used to assess biomarkers and a genetic switch in the biology of the disease. Here we review published data looking at discordance of biomarkers following neoadjuvant chemotherapy and the prognostic and therapeutic implications of the observed discordance. We will review some of the biological explanations to account for the observed discordance and will look at its impact on the role of the pathologist as well as propose essential components required in a pathology report issued for patients receiving neoadjuvant chemotherapy that would help the medical oncologist in treatment planning.
Keywords: Breast cancer, neoadjuvant, biomarker discordance
DOI: 10.3233/CBM-130315
Journal: Cancer Biomarkers, vol. 12, no. 6, pp. 241-250, 2013
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl